Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Related Articles
Transient receptor potential melastatin 8 contributes to… : PAIN
critical contributor to neuropathic cold pain by interacting with the cold sensor transient receptor potential melastatin 8 (TRPM8). By using the St2−/− mice, we demonstrate…
Association of chronic pain with incidence and progression… : PAIN Reports
chronic pain and incidence of CMM and if it existed, to what extent chronic pain relates to the progression of specific CMD-related multimorbidity (MM). Methods:…
Amivantamab With or Without Chemotherapy for Right-Sided Metastatic Colorectal Cancer
Filippo Pietrantonio, MD, discusses updated results from the phase 1b/2 OrigAMI-1 trial, which showed that amivantamab with or without chemotherapy demonstrated durable antitumor activity among…
Heart disease linked to elevated risk for advanced breast cancer
Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a…
Welcome! You are invited to join a webinar: Virtual Tumor Board: GI Malignancy and Inflammatory Bowel Disease . After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: Virtual Tumor Board: GI Malignancy and Inflammatory Bowel Disease . After registering, you will receive a confirmation…
New AI Technology May Have the Potential to Optimize Cancer Surgery
Anant Madabhushi, PhD, and Farzad Fereidouni, PhD, are developing the MarginCall technology to reduce time lag and improve tumor margin assessment accuracy in breast and…
Oxford Myeloma Workshop 2025 | VJHemOnc
The 5th Oxford Myeloma workshop took place on January 30-31, 2025 in Oxford, United Kingdom and brought together clinicians, academic myeloma researchers, and patient advocates…
FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer
The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.
Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report
This case report highlights the sensitivity of a novel MET fusion to capmatinib and emphasizes the need for comprehensive panels in non-small cell lung can
